We Are This Close to "Designer Babies"
By Nina Liss-Schultz,
Mother Jones
| 02. 08. 2016
[cites CGS' Marcy Darnovsky]
Untitled Document
On February 1, scientists from the United Kingdom's Francis Crick Institute got the okay to start research on human embryos using a new genome editing technology called CRISPR. Their work, which will mark only the second time CRISPR has been applied to humans, will use embryos to try to understand the very early stages of human development and pinpoint the genes causing miscarriages and fetal defects.
Not surprisingly, the Crick project has reignited a firestorm of debate over the ethics of human gene editing. "This is the first step in a well mapped-out process heading to genetically modified babies, and a future of consumer eugenics," said Dr. David King, director of Human Genetics Alert, in response to the news.
CRISPR is essentially a cellular scalpel. The small enzyme works by moving through the body's cells and cutting away at precise pieces of the genome—something that's never before been possible to do with such efficiency and ease. Since 2012, it's been used to cut out the gene mutations leading to HIV and sickle cell anemia. Last spring...
Related Articles
By Jacob M. Apel, The Baltimore Sun | 08.16.2024
By Neha Kondaveeti, The Austin Chronicle | 08.16.2024
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...